A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF ROXADUSTAT IN THE TREATMENT OF ANEMIA IN DIALYSIS PATIENTS

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

REPEC

Registry ID

PER-067-14

Enrollment

Registered

2015-02-25

Start date

2015-05-18

Completion date

Unknown

Last updated

2023-09-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Ver Protocolo, Seccion 7.1

Eligibility

Sex/Gender

All

Age

18 Years to 100 Years

Inclusion criteria

Inclusion criteria: Ver Protocolo, Seccion 3.1

Exclusion criteria

Exclusion criteria: Ver Protocolo, Seccion 3.2

Countries

Argentina, Australia, Brazil, Bulgaria, Canada, Czech Republic, Hungary, India, Mexico, Philippines, Poland, Romania, Russian Federation, Slovakia, Spain, Sweden, Thailand, Ukraine, United States, Vietnam

Contacts

Public ContactCarlos Alonso Arbulu

ASTRAZENECA PERU S.A.

carlos.arbulu@astrazeneca.com6101515 Ext. 1573

Outcome results